Generic Name: rivaroxaban
Brand Name: Xarelto
Manufacturer: Bayer Inc.
Manufacturer Requested Reimbursement Criteria1:
For use in combination with low-dose ASA, for the prevention of stroke, myocardial infarction and cardiovascular death in patients with concomitant coronary artery disease (CAD) or peripheral artery disease (PAD).
Submission Type: New Indication
Project Status: Pending
Call For Patient Input: April 25, 2018
Patient Input Closed: June 14, 2018
Anticipated Date: May 24, 2018
Fee Schedule: Pending
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
coronary artery disease, stroke, cardiovascular, heart attack, peripheral vascular disease